On January 9, the net outflow of pharmaceutical and biological funds exceeded 1.2 billion yuan, and 11 shares such as Tongrentang exceeded 50 million

【Pharmaceutical Network Pharmaceutical Stock Market】 The Shanghai Index rose 0.
58% on January 9, and Shenwan's industry rose 28 on January 9, and the top gainers were non-ferrous metals, food and beverage, up 2.
87% and 2.
04%.

The pharmaceutical and biological industry rose 0.
65%
on January 9.
From the perspective of funds, on January 9, there were 18 industries with a net outflow of main funds, and the net outflow of main funds in the pharmaceutical and biological industry was the first, with a net outflow of 1.
247 billion yuan
throughout the day.
From the perspective of the net outflow of funds from the pharmaceutical and biological industry, there are 11 stocks with a net outflow of more than 50 million yuan, and the top net outflows are Tongrentang, Yiling Pharmaceutical and Kanglong Chemical, with a net outflow of 114 million yuan, 111 million yuan and 85.
3857 million yuan
respectively.
According to the data, Tongrentang is mainly engaged in the production and sales of traditional proprietary Chinese medicines, and produces more than 400 specifications of proprietary Chinese medicines all year round, with rich product dosage forms, covering more than 20 product dosage forms
such as pills, powders, wines and capsules, oral liquids, and pills.
Recently, Tongrentang announced that some varieties of the company and its holding subsidiary Beijing Tongrentang Science and Technology Development Co.
, Ltd.
were therefore transferred out of the scope of
Beijing medical insurance drug reimbursement.
Among the company's main product series, the varieties involved in the reimbursement scope of Beijing medical insurance drugs are as follows: Tongren Niuhuang Qingxin Pill is about 142.
06 million yuan, Tongren Daluo Pill is about 65.
63 million yuan, and Liuwei Dihuang Soft Capsule is about 10.
5 million yuan, accounting for 0.
97%, 0.
45% and 0.
07%
of the consolidated sales amount in 2021, respectively 。 In addition, data show that Tongrentang was financed to buy 28.
4623 million yuan on January 9, accounting for 8.
66% of the purchase amount on that day, and the current financing balance is 1.
026 billion yuan, accounting for 1.
76% of the circulating market value; In terms of securities lending, Tongrentang repaid 53,400 shares on January 9, and sold 68,000 shares on margin trading, which was 2,894,100 yuan according to the closing price of the day, accounting for 1.
02%
of the outflow amount on the day.
According to the data, Yiling Pharmaceutical has developed a series of traditional Chinese medicines
with independent intellectual property rights around six major categories of diseases with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurological and urinary diseases, and large market dosage.
At present, Yiling Pharmaceutical has 13 new drugs, of which 8 are listed in the national medical insurance catalogue and 5 are listed in the national essential drug list, which provides an important driving force
for the company's performance growth.
The data shows that Yiling Pharmaceutical was financed to buy 193 million yuan on January 9, accounting for 18.
02% of the purchase amount on that day, and the current financing balance is 1.
627 billion yuan, accounting for 3.
98% of the circulating market value; In terms of securities lending, Ling Pharmaceutical repaid 213,300 shares on January 9, and sold 308,600 shares on margin trading, with a selling amount of 9,159,200 yuan based on the closing price of the day, accounting for 0.
68%
of the outflow amount on the day.
Kanglong Chemicals is one of the global enterprises in the field of drug discovery and occupies an important position
in the domestic CRO market.
Industrial Securities previously said that under the premise that the core drug discovery business maintains stable and rapid growth, the two businesses of CMC and clinical research services will continue to make efforts, which will promote the rapid growth
of Kanglong Chemical's performance.
At the same time, the layout of biological drugs and gene therapy is expected to bring new growth points
for the company's medium and long-term development.
However, Kanglong Chemical announced that on January 9, 2023, the company received the "Simplified Equity Change Report" issued by Kangcheng and its concerted actor Xinzhong Longcheng, a shareholder holding more than 5% of the company's shares: Kangcheng and Longcheng have reduced their holdings of 50,078,330 shares of the company since February 7, 2022, accounting for 5% of the company's
total share capital.
After this equity change, Xinzhong Kangcheng and its concerted actor Xinzhong Longcheng hold a total of 18.
29%
of the company's total share capital.
In addition, data show that Kanglong Chemical was financed to buy 31.
6157 million yuan on January 9, accounting for 8.
62% of the purchase amount on that day, and the current financing balance is 349 million yuan, accounting for 0.
52% of the circulating market value; In terms of securities financing, Kanglong Chemical repaid 260,800 shares on January 9, and sold 35,000 shares on margin trading, which was 2,519,700 yuan according to the closing price of the day, accounting for 0.
83%
of the outflow amount on the day 。 In addition to the above enterprises, on January 9, China Pharmaceutical's net outflow was 84.
9169 million yuan, C'Baili's net outflow was 75.
4192 million yuan, Hengrui Pharmaceutical's net outflow was 71.
875 million yuan, Hanyu Pharmaceutical's net outflow was 68.
6849 million yuan, ST Kangmei's net outflow was 67.
3098 million yuan, Watson Bio's net outflow was 67.
0052 million yuan, Yahong Pharmaceutical's net outflow was 58.
6047 million yuan, and Aier's ophthalmology net outflow was 51.
9204 million yuan
。 Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.